Navigation Links
Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
Date:3/28/2017

SAN DIEGO, March 28, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference, being held April 3, 2017 at the St. Regis Hotel in New York. 

Details for this presentation are as follows:

  • H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference – webcast available
    Time/Date:  3:20 p.m. ET on Monday, April 3, 2017
    Location:  St. Regis Hotel, New York
    Presentation Room:  Versailles Room

To access the live webcast of Viking's presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist in Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking is also developing novel and selective agonists of the thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Follow Viking on Twitter @Viking_VKTX.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-hc-wainwright--cos-1st-annual-nash-investor-conference-300429997.html


'/>"/>
SOURCE Viking Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Viking Therapeutics to Present at the LD Micro Main Event
2. Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
3. Viking Therapeutics to Present at Upcoming Investor Conferences
4. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
5. Leading Alzheimer’s Expert Joins T3D Therapeutics’ Advisory Board
6. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
7. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
8. FACIT Announces Investment in Propellon Therapeutics
9. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
10. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
11. eFFECTOR Therapeutics Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... October 02, 2019 , ... eKare’s inSight® digital 3D imaging and wound measurement ... the East Midlands Academic Health Science Network (EMAHSN), the innovation arm of the NHS. ... providing support to develop and deploy solutions to the most pressing challenges facing the ...
(Date:9/30/2019)... WOODLANDS, Texas (PRWEB) , ... September 30, 2019 ... ... , the materials science newsletter from Rigaku Corporation , is now available ... techniques related to X-ray based materials science, including X-ray diffraction, fluorescence and imaging, ...
(Date:9/24/2019)... and WALTHAM, Mass. (PRWEB) , ... ... ... the leading global provider of advanced delivery technologies, development, and manufacturing solutions ... Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of ...
(Date:9/24/2019)... ... ... In the past three years, the National Science Foundation (NSF) has awarded ... of Mines & Technology that expands human understanding of the microbial world. The ... and yet strong layer which is commonly known as a biofilm. , The broad ...
Breaking Biology Technology:
(Date:10/10/2019)... ... October 09, 2019 , ... Cardea is excited to ... CRISPR-Chip™. Cardea first broke the news of the proposed merger in ... Sensor™. Built with CRISPR-Chip technology, the Genome Sensor is the world’s first DNA ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... new apps that make it easier than ever for businesses and organizations to ... new Countdown App enables organizations to count down to or count up from ...
(Date:10/4/2019)... ... October 03, 2019 , ... Mount Sinai researchers have discovered how ... from one generation to the next. In a study published in Nature Structural & ... this enzyme, leading to cancers and other diseases. , “DNA polymerase delta serves as ...
Breaking Biology News(10 mins):